Evidence map›Paper›PMID 27308532›Full record

ArticleMolecular & cellular oncology2016

Ethanolamine: A novel anti-aging agent.

Patrick Rockenfeller, Didac Carmona-Gutierrez, Federico Pietrocola, Guido Kroemer, Frank Madeo

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Patrick RockenfellerInstitute of Molecular Biosciences; NAWI Graz, University of Graz ; Graz, Austria.
Didac Carmona-GutierrezInstitute of Molecular Biosciences; NAWI Graz, University of Graz ; Graz, Austria.
Federico PietrocolaEquipe 11 labellisée par la Ligue contre le Cancer; Centre de Recherche des Cordeliers; Paris, France; Cell Biology and Metabolomics Platforms; Gustave Roussy Comprehensive Cancer Center; Villejuif, France; INSERM; U1138; Paris, France.
Guido KroemerEquipe 11 labellisée par la Ligue contre le Cancer; Centre de Recherche des Cordeliers; Paris, France; Cell Biology and Metabolomics Platforms; Gustave Roussy Comprehensive Cancer Center; Villejuif, France; INSERM; U1138; Paris, France; Université Paris Descartes; Sorbonne Paris Cité; Paris, France; Université Pierre et Marie Curie, Paris, France; Pôle de Biologie; Hôpital Européen Georges Pompidou; AP-HP; Paris, France.
Frank MadeoInstitute of Molecular Biosciences; NAWI Graz, University of Graz; Graz, Austria; BioTechMed-Graz; Graz, Austria.
Nawi Graz · ATCentre de Recherche des Cordeliers · FRWeatherford College · US

Funding

Austrian Science Fund FWF P 23490Austrian Science Fund FWF P 24381
6 · The paper itself

Abstract

Ethanolamine (Etn) is a naturally occurring aminoalcohol necessary for synthesis of the phospholipid phosphatidylethanolamine (PE), a major component of biological membranes. We recently reported that Etn treatment increases cellular PE levels, thereby inducing cytoprotective autophagy and protecting against aging across species.

Indexed as

agingautophagyethanolaminephosphatidylethanolaminephosphatidylserine decarboxylase

Identifiers

PMID27308532
PMCPMC4845168
OpenAlexW2252439637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.